{"id":"epag-pfos","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombotic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EPAG-pfos activates the thrombopoietin (TPO) receptor on megakaryocyte progenitor cells, promoting their differentiation and maturation into megakaryocytes, which subsequently produce platelets. This mechanism increases circulating platelet counts in patients with low platelet levels due to various causes, including immune thrombocytopenia and chemotherapy-induced thrombocytopenia.","oneSentence":"EPAG-pfos is a thrombopoietin receptor agonist that stimulates platelet production to treat thrombocytopenia.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:02.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia (ITP)"},{"name":"Chemotherapy-induced thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT07476846","phase":"NA","title":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":112},{"nctId":"NCT07189910","phase":"PHASE4","title":"Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-12-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":150},{"nctId":"NCT07001397","phase":"PHASE3","title":"Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-06-23","conditions":"Aplastic Anemias","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"EPAG-pfos","genericName":"EPAG-pfos","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EPAG-pfos is a thrombopoietin receptor agonist that stimulates platelet production to treat thrombocytopenia. Used for Immune thrombocytopenia (ITP), Chemotherapy-induced thrombocytopenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}